Boostrix Articles
GlaxoSmithKline gets US FDA approval for Boostrix to prevent tetanus, diphtheria and pertussis in older people
11 July 2011
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
US FDA approves GSK's Boostrix
15 December 2008
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK's Boostrix approved by US FDA
9 May 2005
GlaxoSmithKline files Boostrix BLA in USA
19 July 2004
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Showing 1-11 of 11 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
